InsidersTradesSigma
Track the Sharp Therapeutics Corp. share price and the full directors' dealings record of the company, a publicly traded company based in Canada. Shares are listed on the CA market, under the supervision of SEDI. Market capitalisation: €1.8bn. The latest transaction was disclosed on 7 August 2026 (16 - Acquisition or disposition under a prospectus exemption). Among the most active insiders: Newlin, William R.. The full history is accessible without an account.
Analysts rate Sharp Therapeutics Corp. Strong Buy (bullish), based on 7 analysts. Average price target: US$15.33.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Sharp Therapeutics Corp. is a company focused on developing innovative therapeutic solutions. It is listed on the XTSE market.